Alnylam price target lowered to $283 from $284 at Canaccord

Canaccord lowered the firm’s price target on Alnylam to $283 from $284 and keeps a Buy rating on the shares. The firm saidthe big news from ots Q4 report was the changes to HELIOS-B’s statistical analysis plan affecting both primary/secondary endpoint structure and the trial’s duration. These changes delay the readout to late June/early July.